Treatment Resistant Disorders
10
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
10.0%
1 terminated out of 10 trials
75.0%
-11.6% vs benchmark
20%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (10)
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
rTMS Effect on Cognitive and Psychiatric Dysfunction in Patients With Fibromyalgia
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)
Correlation of Audiovisual Features With Clinical Variables and Neurocognitive Functions in Bipolar Disorder, Mania
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma
Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome